Lila Sciences, a Flagship Pioneering-backed startup, secured $235 million in a Series A financing round to develop AI-based 'scientific superintelligence' platforms aimed at accelerating drug discovery. The company focuses on integrating artificial intelligence more deeply into laboratory research processes to overcome current bottlenecks. This substantial funding underscores confidence in automating and enhancing biomedical research with AI technologies, promising to transform conventional drug development paradigms.